MedTrace Logo

Clinical Trials

NCT04037254 | COMPLETED | PHASE1/PHASE2
22 participants

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-20
Start Date:
2019-10-08
Completion:
2024-07-01
Conditions
  • Prostate Adenocarcinoma
  • Stage IIC Prostate Cancer AJCC v8
  • Stage III Prostate Cancer AJCC v8
  • Stage IIIA Prostate Cancer AJCC v8
  • Stage IIIB Prostate Cancer AJCC v8
  • Stage IIIC Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8
Interventions
  • BIOLOGICAL
  • RADIATION
  • DRUG
Results Available
NCT03896269 | RECRUITING | PHASE1
38 participants

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-20
Start Date:
2019-05-14
Completion:
2027-12-31
Conditions
  • Blasts 10-19 Percent of Bone Marrow Nucleated Cells
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
  • High Risk Chronic Myelomonocytic Leukemia
  • Recurrent Chronic Myelomonocytic Leukemia
  • Recurrent High Risk Myelodysplastic Syndrome
  • Refractory Chronic Myelomonocytic Leukemia
  • Refractory High Risk Myelodysplastic Syndrome
Interventions
  • DRUG
No Results Yet
NCT03879876 | COMPLETED | PHASE1/PHASE2
4 participants

Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-20
Start Date:
2020-05-13
Completion:
2023-09-03
Conditions
  • Pediatric Patients
  • Any Type of Severe Combined Immunodeficiency (SCID)
  • Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
  • DRUG
No Results Yet
NCT03672539 | ACTIVE_NOT_RECRUITING | PHASE2
50 participants

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-20
Start Date:
2018-11-07
Completion:
2027-11-30
Conditions
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • Chronic Myelomonocytic Leukemia
  • High Risk Myelodysplastic Syndrome
  • Myelodysplastic Syndrome
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
Interventions
  • DRUG
  • OTHER
No Results Yet
NCT03613532 | ACTIVE_NOT_RECRUITING | PHASE1
102 participants

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-20
Start Date:
2018-10-24
Completion:
2026-05-05
Conditions
  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • Chronic Myelomonocytic Leukemia (CMML)
  • MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)
  • Hematopoietic Stem Cell Transplant
Interventions
  • DRUG
No Results Yet
NCT03594630 | RECRUITING | EARLY_PHASE1
120 participants

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-20
Start Date:
2024-03-13
Completion:
2026-10-31
Conditions
  • Rectal Adenocarcinoma
  • Stage II Rectal Cancer AJCC v8
  • Stage IIA Rectal Cancer AJCC v8
  • Stage IIB Rectal Cancer AJCC v8
  • Stage IIC Rectal Cancer AJCC v8
  • Stage III Rectal Cancer AJCC v8
  • Stage IIIA Rectal Cancer AJCC v8
  • Stage IIIB Rectal Cancer AJCC v8
  • Stage IIIC Rectal Cancer AJCC v8
Interventions
  • DRUG
  • OTHER
  • PROCEDURE
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page